UROGEN PHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.3 USD | +0.28% |
|
+1.06% | -4.67% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 700.1 | 398.1 | 213.2 | 204.8 | 463 | 487.9 | - | - |
| Enterprise Value (EV) 1 | 650.4 | 345.3 | 124.1 | 202.4 | 424.6 | 432.3 | 210.9 | 366.4 |
| P/E ratio | -6.52 x | -3.05 x | -1.92 x | -1.85 x | -4.23 x | -3.98 x | -8.56 x | 10 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 38,894 x | 33.7 x | 4.44 x | 3.18 x | 5.6 x | 4.93 x | 2.69 x | 1.61 x |
| EV / Revenue | 36,133 x | 29.3 x | 2.58 x | 3.14 x | 5.13 x | 4.37 x | 1.16 x | 1.21 x |
| EV / EBITDA | -5.96 x | -2.73 x | -1.36 x | -2.59 x | -6.56 x | -5 x | -2.51 x | -14.4 x |
| EV / FCF | -9,116,658 x | -3,223,619 x | -1,448,768 x | -2,304,689 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 3.89 x | 4.07 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,980 | 22,093 | 22,420 | 23,090 | 30,866 | 34,122 | - | - |
| Reference price 2 | 33.37 | 18.02 | 9.510 | 8.870 | 15.00 | 14.30 | 14.30 | 14.30 |
| Announcement Date | 20-03-02 | 21-03-18 | 22-03-21 | 23-03-16 | 24-03-14 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.018 | 11.8 | 48.04 | 64.36 | 82.71 | 99.02 | 181.3 | 303.3 |
| EBITDA 1 | -109.2 | -126.3 | -91.46 | -78.12 | -64.73 | -86.42 | -84.17 | -25.52 |
| EBIT 1 | -109.5 | -126.7 | -92.29 | -79.04 | -65.54 | -86.48 | -33.97 | 54.29 |
| Operating Margin | -608,211.11% | -1,074.15% | -192.11% | -122.82% | -79.23% | -87.34% | -18.73% | 17.9% |
| Earnings before Tax (EBT) 1 | -105.1 | -125.1 | -109.4 | -108 | -98.32 | -126.9 | -87.02 | -19.5 |
| Net income 1 | -105.1 | -128.5 | -110.8 | -109.2 | -102.2 | -125.6 | -62.13 | 52.58 |
| Net margin | -584,144.44% | -1,088.94% | -230.67% | -169.62% | -123.61% | -126.82% | -34.26% | 17.34% |
| EPS 2 | -5.120 | -5.900 | -4.960 | -4.790 | -3.550 | -3.592 | -1.670 | 1.425 |
| Free Cash Flow | -71.34 | -107.1 | -85.64 | -87.81 | - | - | - | - |
| FCF margin | -396,344.44% | -907.71% | -178.27% | -136.45% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-02 | 21-03-18 | 22-03-21 | 23-03-16 | 24-03-14 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.35 | 16.17 | 13.56 | 16.6 | 16.1 | 18.09 | 17.19 | 21.14 | 20.85 | 23.53 | 21.39 | 25.18 | 25.37 | 27.07 | 32.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.44 | -19.92 | -21.96 | -18.72 | -18.09 | -20.28 | -22.04 | -15.38 | -13.5 | -14.61 | -20.4 | -19.16 | -21.83 | -25.09 | - |
| Operating Margin | -206.5% | -123.13% | -161.88% | -112.71% | -112.36% | -112.1% | -128.23% | -72.77% | -64.74% | -62.09% | -95.36% | -76.11% | -86.05% | -92.66% | - |
| Earnings before Tax (EBT) 1 | -30.21 | -27.32 | -28.07 | -26.66 | -25.12 | -28.18 | -30.19 | -24.08 | -21.89 | -22.16 | -30.09 | -30.44 | -32.81 | -33.6 | - |
| Net income 1 | -30.21 | -28.45 | -28.39 | -26.69 | -25.83 | -28.25 | -30.21 | -24.14 | -21.88 | -26.02 | -30.26 | -29.97 | -32.87 | -32.47 | - |
| Net margin | -266.15% | -175.91% | -209.32% | -160.75% | -160.47% | -156.14% | -175.74% | -114.18% | -104.93% | -110.57% | -141.48% | -119.03% | -129.54% | -119.92% | - |
| EPS 2 | -1.350 | -1.270 | -1.250 | -1.180 | -1.130 | -1.220 | -1.300 | -1.030 | -0.6800 | -0.7200 | -0.8875 | -0.8725 | -0.9275 | -0.9075 | -0.7300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-15 | 22-03-21 | 22-05-10 | 22-08-11 | 22-11-10 | 23-03-16 | 23-05-11 | 23-08-10 | 23-11-14 | 24-03-14 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 49.7 | 52.9 | 89.1 | 2.43 | 38.4 | 55.6 | 277 | 122 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -71.3 | -107 | -85.6 | -87.8 | - | - | - | - |
| ROE (net income / shareholders' equity) | -77.8% | -92.9% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -68.7% | -79.2% | - | - | - | - | - | - |
| Assets 1 | 153 | 162.2 | - | - | - | - | - | - |
| Book Value Per Share | 8.580 | 4.420 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.33 | 1.22 | - | - | - | - | - | - |
| Capex / Sales | 1,805.56% | 10.3% | - | - | - | - | - | - |
| Announcement Date | 20-03-02 | 21-03-18 | 22-03-21 | 23-03-16 | 24-03-14 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.3
USD
Average target price
38.5
USD
Spread / Average Target
+169.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.67% | 488M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- URGN Stock
- Financials UroGen Pharma Ltd.
